Global management of taxidermy;Prise en charge globale des toxidermies

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 4, 2007, Pages 391-401

  Barbaud, A ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM; PENICILLIN G;

ALLERGIC REACTION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; HUMAN; INJECTION SITE RASH; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; MACULOPAPULAR RASH; PHOTOALLERGY; REVIEW; SKIN TOXICITY; STEVENS JOHNSON SYNDROME;

EID: 34248344562     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(07)89201-5     Document Type: Article

References (64)

1. Barbaud A. Toxidermies immunoallergiques chez l'immunocompétent. Encyclopédie médicochirurgicale, 2004, 98-478-A-10:1-7.
2. Barbaud A. Démarche diagnostique devant une toxidermie. Concours Médical 2003;125:1259-66.
3. Djien V, Bocquet H, Dupuy A, Revuz J, Roujeau JC. Symptomatologie et marqueurs de sévérité des toxidermies érythé mateuses. Ann Dermatol Venereol 1999;126:247-50.
4. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8:5.
5. Silverman E, In KH, Yandava C, Drazen M. Pharmacogenetics of the 5-lipoxygenase pathway in asthma. Clin Exp Allergy 1998;28:164s-170s.
6. Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005;137:145-50.
7. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother 2000;34:526-8.
8. Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 2004;126:400-4.
9. Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Fenestra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998;158:2063-5.
10. Fays S, Trechot P, Schmutz JL, Cuny JF, Truchetet F, Barbaud A. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol 2003;148:171-2.
11. Chandeclerc ML, Martin S, Petitpain N, Barbaud A, Schmutz JL. Tadalafil and palpebral edema. South Med J 2004;97:1142-3.
12. Cousin F, Catelain A, Philips K, Favier B, Queuille E, Nicolas JF. L'hypersensibilité immédiate est rarement en cause dans les urticaires médicamenteuses. Ann Dermatol Venereol 2003;130:321-4.
13. Balint G, Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 1996;45:s91-95.
14. Teraki Y, Shiohara T. Fixed drug eruption as a localized and mildform of toxic epidermal necrolysis. Ann Dermatol Venereol 2002;129:1s35.
15. Alanko K. Topical provocation of fixed drug eruption: a study of 30 patients. Contact Dermatitis 1994;31:25-7.
16. Figarella I, Barbaud A, Lecompte T, De Maistre E, Reichert-Penetrat S, Schmutz JL. Réaction cutanée d'hypersensibilité retardée avec polysensibilisation aux héparines et héparinoïdes. Ann Dermatol Venereol 2001;128:25-30.
17. Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 2004;51:149-50.
18. Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in infectious mononucleosis: a proposed mechanism of interaction. Cutis 2000;65:163-6.
19. Martin S, Barbaud A, Schmutz JL, Gobert B, Faure G, Béné MC. Polyclonalité de la réponse lymphocytaire T dans les tests d'activation lymphocytaire médicamenteux. Ann Dermatol Venereol 2000;127:268-72.
20. Mauri-Helweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, et al. Cross-reactivity of T cell clones to beta-lactam antibiotics. J Immunol 1996;157:1071-9.
21. Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139:49-58.
22. Barbaud A, Bene MC, Faure G, Schmutz JL. Tests cutanés dans l'exploration des toxidermies supposées de mécanisme immuno-allergique. Bull Acad Natle Med 2000;184:47-63.
23. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321-8.
24. Romano A, Quarantino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. À diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol 1999;103:1186-90.
25. Beylot C, Bioulac P, Doutre MS. Pustulose exanthématique aiguë généralisée (quatre cas). Ann Dermatol Venereol 1980;107:37-48.
26. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP). À clinical reaction pattern. J Cutan Pathol 2001;28:113-9.
27. Roujeau JC, Bioulac Sage P, Bourseau C, Guillaume JC, Bermard P, Lok C, et al. Acute generalized exanthematous pustulosis. Arch Dermatol 1991;127:1333-8.
28. Britschgi M, Steiner UC, Schmid S, Depta JPH, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001;107:1433-41.
29. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dumé L, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996;35:234-6.
30. Sparsa A, Loustaud-Ratti V, Mousset-Hovaere M, de Vençay P, Le Brun V, Liozon E, et al. Syndrome d'hypersensibilité mé dicamenteuse en pratique interniste : pièges diagnostique et thérapeutique. Huit observations. Rev Med Interne 2000;21:1052-9.
31. Cordel N, Lenormand B, Courville P, Lauret P, Joly P. Détection du réarrangement clonal du gène gamma du récepteur des cellules T par PCR-DGGE pour le diagnostic des érythrodermies. Ann Dermatol Venereol 2001;128:220-3.
32. Descamps V, Valance A, Eldinger C, Fillet AM, Grossin M , Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
33. Hashimoto K, Yasukawa M, Tohyama M. Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 2003;3:255-60.
34. Janela B, Descamps V, Picard D, Rogez S, D'Incan M, Bernard P, et al. Rôle des réactivations virales sur la réponse lymphocytaire T au cours du syndrome d'hypersensibilité médicamenteuse. Ann Dermatol Venereol 2005;132:9s37.
35. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004;140:183-8.
36. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005;209:209-16.
37. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:s28-s30.
38. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
39. Bergoend H, Loffler A, Amar R, Maleville J. Réactions cutanées apparues durant une prophylaxie de masse de la méningite cérébrospinale avec un sulfamide d'action retardée. À propos de 997 cas. Ann Dermatol Venereol 1968;95:481-90.
40. Barbaud A. Physiopathologie de l'érythème polymorphe. Ann Dermatol Venereol 1998;125:799-805.
41. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.
42. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC, SCAR study Group. Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138: 1019-24.
43. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995;131:539-43.
44. Côté B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995;131:1268-72.
45. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1997;133:845-9.
46. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-4.
47. Hertl M, Bohlen H, Jugert F, Boecker C, Knaup R, Merk HF. Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics. J Invest Dermatol 1993;101:794-9.
48. Ito K, Hara H, Okada T, Shimojima H, Suzuki H. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-Ligand expression. Clin Exp Dermatol 2004;29:679-80.
49. Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004;51:297-310.
50. Barbaud A, Trechot P, Reichert-Penetrat S, Commun N, Schmutz JL. Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis 2001;45:265-8.
51. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 2002;47:100-2.
52. Barbaud A, Bursztejn A, Vernassiere C, Schmutz JL, Tréchot P. Toxidermie à l'Aérius® : les patch tests avec la desloratadine induisent des faux positifs. Ann Dermatol Venereol 2005;132:s71.
53. Demoly P. Anaphylactic reactions-value of skin and provocation tests. Toxicology 2005;209:221-3.
54. Ponvert C, Le Clainche L, de Blic J, Le Bourgeois M, Scheinmann P, Paupe J. Allergy to beta-lactam antibiotics in children. Pediatrics 1999;104:e45.
55. Romano A, Gueant-Rodriguez RM, Viola M, Pettinato R, Gueant JL. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004;141:16-22.
56. Messaad D, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004;140:1001-6.
57. Waton J, Tréchot P, Cuny JF, Schmutz JL, Barbaud A. Valeur prédictive négative des tests cutanés dans l'exploration des toxidermies. Ann Dermatol Venereol 2005;132:s79.
58. Baldo BA. Penicillins and cephalosporins as allergens-structural aspects of recognition and cross-reactions. Clin Exp Allergy 1999;29:744-9.
59. Romano A, Gueant-Rodriguez RM, Viola M, Gaeta F, Caruso C, Gueant JL. Cross-reactivity among drugs: clinical problems. Toxicology 2005;209:169-79.
60. Perez-Inestrosa E, Suau R, Montanez MI, Rodriguez R, Mayorga C, Torres MJ, Blanca M. Cephalosporin chemical reactivity and its immunological implications. Curr Opin Allergy Clin Immunol 2005;5:323-30.
61. Blanca M, Cornejo-Garcia JA, Torres MJ, Mayorga C. Specificities of B cell reactions to drugs. The penicillin model. Toxicology 2005;209:181-4.
62. Barbaud A, Tréchot P, Weber-Muller F, Ulrich G, Commun N, Schmutz JL. Drug skin tests in cutaneous adverse drug reactions to pristinamycin: 29 cases with a study of cross-reactions between synergistins. Contact Dermatitis 2004;50:22-6.
63. Vernassiere C, Barbaud A, Tréchot PH, Weber-Muller F, Schmutz JL. Systemic acyclovir reaction subsequent to acyclovir contact allergy: which systemic antiviral drug should then be used? Contact Dermatitis 2003;49:155-7.
64. Cholez C, Tréchot P, Schmutz JL, Faure G, Bene MC, Barbaud A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy 2003;58:1207-9.